SNBL’s Subsidiary Resubmits Migraine Drug Application
Company Announcements

SNBL’s Subsidiary Resubmits Migraine Drug Application

Shin Nippon Biomedical Laboratories, Ltd. (JP:2395) has released an update.

Shin Nippon Biomedical Laboratories’ subsidiary, Satsuma Pharmaceuticals, has resubmitted its New Drug Application for STS101, a treatment for acute migraine, to the FDA, addressing previous concerns about formulation while receiving no requests for additional clinical trials. This move is seen as pivotal in offering new options for migraine sufferers.

For further insights into JP:2395 stock, check out TipRanks’ Stock Analysis page.

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App